A drug originally used to boost the immune system is showing promise as a potential new treatment for lupus, joint Monash University and Peking University research published today shows. Lupus is an autoimmune disease, where the immune system attacks the body’s own organs and tissues.
An international team of scientists from Australia and China have, for the first time, shown in a study published in Nature Medicine, that a natural immune system protein called IL-2 can help restore balance to the overactive immune system of lupus patients. The drug could soon be rolled out for clinical trials in lupus treatment.
Monash Biomedicine Discovery Institute researcher, Dr Di Yu and Professor Zhanguo Li from Peking University People’s Hospital in China co-led the study.
Dr Yu said he hoped the drug could be approved as a lupus treatment within a handful of years.
“This drug, which can help the immune system fight against cancer, was approved in the 1990s but is not commonly used now. We’re now using this drug for a different purpose, based on our new knowledge of the immune system,” Dr Yu said.
“The amount we tested for treating lupus is much less than the dose used in treating cancers. We observed the treatment was safe and showed promising results, so there’s reason to believe formal trials could begin almost immediately,” he said.
Dr Yu said lupus could be a serious disease, and that it hadn’t been able to be treated in a very satisfactory way in the past.
IL-2 is a protein that regulates the activity of white blood cells, which are an important part of the immune system that protect the body against infections. In cancer therapy, patients are given large doses of IL-2 to stimulate their immune system but, paradoxically, the low dose IL-2 given to lupus sufferers in this study actually supressed the overactive part of their immune system that attacks their body. The research also showed the “self-checking” part of the immune system that prevents an overactive immune response, called regulatory T cells, increased after IL-2 treatment.
Professor Eric Morand, fellow Monash University researcher on the study and founder of the Asia Pacific Lupus Collaboration, said that in this study, IL-2 was given to people whose lupus wasn’t responding well to standard treatments.
“The real promise of this treatment is that it calms the hyperactive immune system through multiple mechanisms, which is very important as this new therapy may be effective for many patients,” Professor Morand said.
”As the drug has been on the market for some time for other diseases, it can be rapidly put into formal trials for lupus treatment right away.”
Learn more: Promising new treatment for lupus on the horizon
The Latest on: Lupus
via Google News
The Latest on: Lupus
- BRIEF-Janssen Announces Discontinuation Of Phase 3 Lotus Study Evaluating Ustekinumab In Systemic Lupus Erythematosuson June 26, 2020 at 5:00 pm
JANSSEN PHARMACEUTICAL - TO DISCONTINUE PHASE 3 LOTUS STUDY OF STELARA IN SYSTEMIC LUPUS ERYTHEMATOSUS DUE TO LACK OF EFFICACY IN SLE * JANSSEN PHARMACEUTICAL - DECISION TO DISCONTINUE LOTUS STUDY ...
- J&J bails on Stelara for lupuson June 26, 2020 at 10:36 am
JNJ) unit Janssen Pharmaceutical Companies will terminate its Phase 3 LOTUS study evaluating Stelara (ustekinumab) in patients with an autoimmune disorder called systemic l ...
- J&J scraps late-stage study testing Stelara for lupuson June 26, 2020 at 5:28 am
Johnson & Johnson's Janssen unit said on Friday it would discontinue a late-stage study testing its psoriatic arthritis drug Stelara as a treatment for lupus as it was not found to be effective ...
- Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosuson June 26, 2020 at 5:00 am
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of ...
- Lupus Nephritis Market 2020 Top Manufacturers, Industry Share, Size, Regional Analysis, Types and Applications and Forecasts to 2025on June 25, 2020 at 4:29 am
Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Lupus Nephritis Market” ...
- Systemic Lupus Erythematosus Market Will Exceed $2.7 Bn By 2026 | CAGR: 7%on June 24, 2020 at 3:59 am
The global Systemic Lupus Erythematosus Market size is expected to reach USD 2.7 billion by 2026, at a significant growth rate of 7% during the forecasted period 2020 to 2026. The market report ...
- Lupus Foundation of America Survey Finds Over Half of Respondents Experienced Issues Accessing Hydroxychloroquine During Coronavirus Pandemicon June 23, 2020 at 8:52 am
The survey includes responses from 3,000 people with lupus and caregivers, with 90% taking antimalarials. Respondents represented every state including DC and Puerto Rico.
- Relief for lupus patients in America after hydroxychloroquine no longer seen as cure for COVID-19 | Videoon June 21, 2020 at 5:39 am
Scientific proof now shows that the anti-malarial drug hydroxychloroquine, once touted as a miracle cure for COVID-19, might be of more harm than help to coronavirus patients. Those that need the drug ...
- Alpine Immune Sciences stock rises after landing $60M from AbbVie for lupus drugon June 19, 2020 at 9:34 am
Alpine Immune Sciences stock rose more than 10% Friday after the Seattle-based biotech company inked a $60 million licensing deal with pharmaceutical giant AbbVie for its lupus drug.
- Global Drug Forecast and Market Analysis for Systemic Lupus Erythematosus and Lupus Nephritis to 2027on June 16, 2020 at 6:24 pm
The "Systemic Lupus Erythematosus and Lupus Nephritis: Global Drug Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering. Systemic lupus erythematosus (SLE) ...
via Bing News